Your session is about to expire
← Back to Search
Combination Therapies + Lifestyle Modifications for Traumatic Brain Injury (CoINTEGRATE Trial)
N/A
Recruiting
Led By Hala Darwish, PhD
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 9 (after treatment ended)
Awards & highlights
No Placebo-Only Group
Summary
This trial tests if combining talking therapy, brain exercises, and lifestyle changes can help people with neurocognitive disorders live better lives by improving their thinking, brain function, and daily habits.
Who is the study for?
This trial is for adults over 50 with mild cognitive impairment (MCI) or those aged 21-65 with traumatic brain injury (TBI), multiple sclerosis (MS), or long COVID, experiencing certain levels of cognitive decline. They must be part of the Michigan medicine network and able to consent. Excluded are individuals with severe depression, suicidal thoughts, other major neurological conditions, recent MS relapse, diagnosed sleep disorders, sensory impairments, substance abuse issues, or currently in similar therapies.
What is being tested?
The CoINTEGRATE study tests a tailored mix of Cognitive Behavioral Therapy (CBT), Cognitive Rehabilitation Therapy (CRT), and lifestyle changes against usual care to see if it improves life quality and community integration for people with neurocognitive disorders resulting from TBI or MS.
What are the potential side effects?
Since this trial involves therapy and lifestyle adjustments rather than medication, typical medical side effects are not expected. However, participants may experience emotional discomfort when discussing personal issues during CBT sessions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 9 (after treatment ended)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 9 (after treatment ended)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Overall experience based qualitative semi-structured interview
Secondary study objectives
Brief Visuospatial Memory test (BVMT-R-25 minutes)
California Verbal Learning Test-Third Edition (CVLT-3-60 minutes)
Montreal Cognitive Assessment (MoCA)
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: CRT plus CBT and Lifestyle modificationsExperimental Treatment3 Interventions
Group II: Usual careActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CBT
2013
Completed Phase 3
~4220
CRT
2008
Completed Phase 4
~860
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Cognitive Behavioral Therapy (CBT) works by helping patients identify and change negative thought patterns and behaviors, thereby improving emotional regulation and reducing symptoms of anxiety and depression. Cognitive Rehabilitation Therapy (CRT) focuses on enhancing cognitive functions such as memory, attention, and problem-solving through structured tasks and exercises.
Lifestyle modifications, including physical activity, diet, and social engagement, aim to improve overall brain health and quality of life. These treatments are crucial for Neurocognitive Disorder patients as they address both cognitive deficits and emotional well-being, promoting better community integration and enhancing quality of life.
Treatment approaches for pusher behaviour: a scoping review.Evaluation of the Effectiveness of a Multimodal Complementary Medicine Program for Improving the Quality of Life of Cancer Patients during Adjuvant Radiotherapy and/or Chemotherapy or Outpatient Aftercare.Feasibility and acceptability of brief cognitive remediation targeting metacognition in acute inpatients with psychosis: a case series.
Treatment approaches for pusher behaviour: a scoping review.Evaluation of the Effectiveness of a Multimodal Complementary Medicine Program for Improving the Quality of Life of Cancer Patients during Adjuvant Radiotherapy and/or Chemotherapy or Outpatient Aftercare.Feasibility and acceptability of brief cognitive remediation targeting metacognition in acute inpatients with psychosis: a case series.
Find a Location
Who is running the clinical trial?
University of MichiganLead Sponsor
1,861 Previous Clinical Trials
6,440,981 Total Patients Enrolled
10 Trials studying Dementia
1,725 Patients Enrolled for Dementia
Hala Darwish, PhDPrincipal InvestigatorUniversity of Michigan
1 Previous Clinical Trials
1 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My cognitive abilities are within normal range for my age and education.I have had mild cognitive impairment for over a year.I experience symptoms like headache or dizziness from a brain injury.I have been diagnosed with TBI, MS, Long COVID, or MCI.I have been diagnosed with cognitive impairment in learning, memory, or processing speed.I have been diagnosed with COVID-19.I do not have severe depression or thoughts of harming myself.I am over 50 with MCI or between 21-65 with another diagnosis and am treated within the Michigan medicine network.I have a visual or hearing impairment.I am currently in therapy, such as cognitive, behavioral, or occupational.I have cognitive issues in learning, memory, or processing speed.I have MS and recently had a relapse or am on steroids.I have been diagnosed with a sleep disorder.
Research Study Groups:
This trial has the following groups:- Group 1: Usual care
- Group 2: CRT plus CBT and Lifestyle modifications
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.